OMERS Administration Corp’s Japer Therapeutics Warrants JSPRW Stock Holding History

OMERS Administration Corp’s Portfolio JSPRW Stock Details JSPRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21,300	Closed	-$17K	–	61
2021 Q1	$17K	Sell	21,300 -21,200	-50%	-$31K	﹤0.01%	400
2020 Q4	$62K	Buy	+42,500	New	+$53.3K	﹤0.01%	258

Other funds holding JSPRW

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return

OMERS Administration Corp's JSPRW Position: Q2 2021 in Review

OMERS Administration Corp sold out of Japer Therapeutics Warrants (JSPRW) in Q2 2021, closing a stake of 21,300 shares — an estimated $17K sold.

OMERS Administration Corp first reported a position in JSPRW in Q4 2020 and held it in 2 quarters. The position peaked at $62K in Q4 2020. 20 funds tracked by Wall St. Rank hold JSPRW as of Q2 2021.

OMERS Administration Corp reported no remaining Japer Therapeutics Warrants position as of Q2 2021 after selling out during the quarter.
OMERS Administration Corp sold 21,300 Japer Therapeutics Warrants shares in Q2 2021, an estimated $17K.
OMERS Administration Corp first reported a position in Japer Therapeutics Warrants in Q4 2020 and held it in 2 quarters.
OMERS Administration Corp's Japer Therapeutics Warrants position peaked at $62K in Q4 2020.
20 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q2 2021.

Based on OMERS Administration Corp's 13F filing for Q2 2021, filed 13 Aug 2021.